ATE232087T1 - Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes - Google Patents

Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes

Info

Publication number
ATE232087T1
ATE232087T1 AT98955458T AT98955458T ATE232087T1 AT E232087 T1 ATE232087 T1 AT E232087T1 AT 98955458 T AT98955458 T AT 98955458T AT 98955458 T AT98955458 T AT 98955458T AT E232087 T1 ATE232087 T1 AT E232087T1
Authority
AT
Austria
Prior art keywords
dispersions
active substance
poorly water
solid solutions
soluble active
Prior art date
Application number
AT98955458T
Other languages
English (en)
Inventor
Siva Narayan Tallavajhala
Xiuying Liu
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE232087T1 publication Critical patent/ATE232087T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98955458T 1997-10-27 1998-10-15 Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes ATE232087T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6333897P 1997-10-27 1997-10-27
PCT/EP1998/006544 WO1999021534A1 (en) 1997-10-27 1998-10-15 Solid state solutions and dispersions of poorly water soluble drugs

Publications (1)

Publication Number Publication Date
ATE232087T1 true ATE232087T1 (de) 2003-02-15

Family

ID=22048528

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955458T ATE232087T1 (de) 1997-10-27 1998-10-15 Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes

Country Status (10)

Country Link
EP (1) EP0996429B1 (de)
JP (1) JP2001520984A (de)
CN (1) CN1190187C (de)
AT (1) ATE232087T1 (de)
DE (1) DE69811233T2 (de)
DK (1) DK0996429T3 (de)
ES (1) ES2191977T3 (de)
NO (1) NO329755B1 (de)
PT (1) PT996429E (de)
WO (1) WO1999021534A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
WO1999063841A1 (en) * 1998-06-05 1999-12-16 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ES2739023T3 (es) * 2001-07-06 2020-01-28 Veloxis Pharmaceuticals As Aglomeración controlada
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
CN1310648C (zh) * 2002-12-13 2007-04-18 佳高泰克有限公司 局部纳米颗粒螺甾内酯制剂
US20040162333A1 (en) * 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
CA2518903C (en) 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
ES2414705T3 (es) 2003-06-20 2013-07-22 Ares Trading S.A. Formulaciones liofilizadas de FSH/LH
MXPA06005461A (es) * 2003-11-13 2006-12-15 Johnson & Johnson Dispersiones de mezclas en estado fundido que comprenden un farmaco de baja solubilidad en agua y un copolimero de bloque de oxido de etileno-oxido de propileno.
JP2007517016A (ja) 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
PL1962808T3 (pl) * 2005-12-14 2011-03-31 Hoffmann La Roche Preparat proleku przeciw HCV
PT2054040E (pt) * 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
EP1972336A1 (de) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Heißschmelz-Mikropellets
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
JP2013512948A (ja) * 2009-12-08 2013-04-18 イル・ファ・カンパニー・リミテッド 20−O−β−D−グルコピラノシル−20(S)−プロトパナキサジオールを含む固体分散体
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
SG10201508982TA (en) * 2010-11-01 2015-12-30 Melinta Therapeutics Inc Pharmaceutical compositions
EP2455068A1 (de) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmazeutische Zusammensetzung zur Behandlung von HCV-Infektionen
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
WO2014176389A1 (en) 2013-04-24 2014-10-30 Temple University - Of The Commonwealth System Of Higher Education Solid dosage form containing arabinogalactan
JP6666840B2 (ja) * 2013-08-01 2020-03-18 エムダブリュ エンキャップ リミテッド 低水溶性薬剤の低融解イオン性塩の組成物および調製方法
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
EP3492070A1 (de) * 2017-11-30 2019-06-05 BIT Pharma GmbH Verfahren und vorrichtung zur herstellung einer festen dispersion
US20220175677A1 (en) * 2019-04-08 2022-06-09 Cosci Med-Tech Co., Ltd. Methods of improving pharmaceutical substance solubilization and products thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5487887A (en) * 1993-10-28 1996-01-30 Bristol-Myers Squibb Company Clear antiperspirant roll-on compositions
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
JPH08268878A (ja) * 1995-03-06 1996-10-15 Yoshiyuki Masui 経口医薬品並びに加工食品
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates

Also Published As

Publication number Publication date
DK0996429T3 (da) 2003-05-26
NO20002133D0 (no) 2000-04-26
EP0996429B1 (de) 2003-02-05
NO20002133L (no) 2000-04-26
DE69811233D1 (de) 2003-03-13
NO329755B1 (no) 2010-12-13
CN1278164A (zh) 2000-12-27
DE69811233T2 (de) 2003-11-20
CN1190187C (zh) 2005-02-23
ES2191977T3 (es) 2003-09-16
PT996429E (pt) 2003-06-30
EP0996429A1 (de) 2000-05-03
JP2001520984A (ja) 2001-11-06
WO1999021534A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ATE232087T1 (de) Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
SE0102438D0 (sv) New compounds
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
HRP20021009B1 (en) Method for preparing a composition
DE69927963D1 (de) Gelierbare pharmazeutische zusammensetzungen
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
BR0313234A (pt) Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto
DE60006536D1 (de) Antiproliferative imidazol wirkstoffe
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
AP1745A (en) Pharmaceutical compositions of amlodipine and atorvastatin.
CA2426852A1 (en) Formulation containing phosphate derivatives of electron transfer agents
EA200301040A1 (ru) Способ производства фармацевтической композиции низкой дозы
DE69034226D1 (de) Herstellungsverfahren von Huperzine A und deren Analogen und Verbindungen nützlich dazu
DK1383540T3 (da) Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
MA27662A1 (fr) Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
WO2003045326A3 (en) Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
AU2003267551A1 (en) Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
ATE383341T1 (de) Substituierte caprolactam carbonate und ether sowie deren verwendung als anti-tumor wirkstoffe
WO2002003973A3 (en) Compositions comprising isosorbide dinitrate and methods for treatment of anal fissure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0996429

Country of ref document: EP